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Abstract
Context—Delirium is a highly prevalent complication in patients in palliative care settings,
especially in the end-of-life context.
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Objectives—To review the current evidence base for treating episodes of delirium in palliative
care settings and propose a framework for future development.
Methods—We combined multidisciplinary input from delirium researchers and other purposely
selected stakeholders at an international delirium study planning meeting. This was supplemented
by a literature search of multiple databases and relevant reference lists to identify studies
regarding therapeutic interventions for delirium.
Results—The context of delirium management in palliative care is highly variable. The standard
management of a delirium episode includes the investigation of precipitating and aggravating
factors followed by symptomatic treatment with drug therapy. However, the intensity of this
management depends on illness trajectory and goals of care in addition to the local availability of
both investigative modalities and therapeutic interventions. Pharmacologically, haloperidol
remains the practice standard by consensus for symptomatic control. Dosing schedules are derived
from expert opinion and various clinical practice guidelines as evidence-based data from palliative
care settings are limited. The commonly used pharmacologic interventions for delirium in this
population warrant evaluation in clinical trials to examine dosing and titration regimens, different
routes of administration, and safety and efficacy compared with placebo.
Conclusion—Delirium treatment is multidimensional and includes the identification of
precipitating and aggravating factors. For symptomatic management, haloperidol remains the
practice standard. Further high-quality collaborative research investigating the appropriate
treatment of this complex syndrome is needed.
Keywords
Delirium; palliative care; evidence-based medicine; therapeutics; decision making; hospices
Introduction
Delirium is a common neuropsychiatric complication of medical illness across a wide
variety of health care settings. The reported prevalence of delirium in inpatient palliative
care settings ranges from 26%–62% during admission to 88% in the last days and hours of
life.1,2 In addition to the high frequency of delirium in the terminal phase of illness, it has
been independently associated (negatively) with short-term survival.3,4 Delirium is
characterized by a fluctuating constellation of cognitive and neurobehavioral features,
including abnormalities of awareness, attention, perception, psychomotor activity, and
sleep.5 Perhaps unsurprisingly, this complex neuropsychiatric syndrome remains not only
underdiagnosed but also undertreated.6–8
The multifactorial nature of delirium etiology involves a combination of predisposing
baseline risk factors and superimposed precipitating factors, many of which are modifiable.
Delirium has an element of reversibility when precipitants are identified and successfully
removed or minimized. Consequently, across most settings, the standardized approach to
delirium management involves searching for and addressing its underlying precipitants in
addition to optimal symptomatic treatment with drug therapy.9–12 Clinicians sometimes face
a therapeutic dilemma as to how aggressively they pursue delirium precipitants, particularly
in patients who are transitioning to the terminal phase of illness.
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Delirium is disturbing to families in all settings, but especially for those whose family
member is near the end of life when communication and comfort needs are paramount.13,14
Refractory delirium, in which the optimal therapeutic interventions have failed to control its
clinical features, is the most common indication for the use of continuous sedation at the end
of life.15
This article aims to 1) appraise the current evidence base for treatment of clinical delirium in
the context of palliative care (referring to any type of health care setting in which palliation
of a life-threatening illness is indicated) and 2) propose a framework for the future
expansion of this evidence base. Pharmacologic and nonpharmacologic preventive strategies
also constitute an integral part of a comprehensive delirium management plan but are not
addressed in depth in this article.
Methods
This article is based in part on the combined multidisciplinary input from leading delirium
researchers (invitation was based on their publication record); specialist physicians in
oncology, intensive care, geriatric medicine and psychiatry, liaison psychiatry, and palliative
care; and clinical or organizational administrators. This structured process was conducted
through a two day international delirium study planning meeting in June 2012 in Ottawa,
Canada, in which 31 attendees gathered to identify knowledge gaps and research priorities in
relation to delirium in palliative care. The program addressed the symptomatic management
of delirium and included multiple formal presentations in addition to small and large group
discussions, which were recorded and transcribed.
The meeting data were supplemented by a systematic literature search of Ovid MEDLINE,
EMBASE, and Cochrane databases from the earliest available records of each up to April
2013 to identify trials of pharmacologic treatment of delirium. Search terms included
“delirium,” “confusion,” “treatment,” “therapeutics,” “antipsychotic agents,” “alpha
adrenergic agents,” and “cholinesterase inhibitors”; results were limited to the English
language and human clinical trials and systematic reviews. Reference lists of reviews and
included articles also were evaluated for relevant trials. The scope of the search was not
limited to palliative care. The search yielded 430 potentially relevant citations, of which 55
were reviewed. Only prospective single-arm or parallel-arm comparative trials were
retrieved. Thirty-one trials met these inclusion criteria. Although a systematic approach was
used to search the literature, no formal quality review of the selected articles was conducted.
Results
Based on our review objectives, literature search, and deliberations at the international
delirium study planning meeting, we categorized the evidence informing treatment of
clinical delirium into 1) the unique contextual issues in palliative care, 2) pharmacologic
interventions, 3) nonpharmacologic interventions, and 4) recommendations for future
studies.
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Unique Contextual Issues in Palliative Care Settings
Although a certain degree of commonality may exist in relation to some challenging aspects
of delirium management across the many health care settings and populations in which it
occurs, the relatively unique contextual issues relating to palliative care warrant specific
recognition and consideration. These issues include the vulnerability of the patient
population, cognitive status and its implications for care, determining the reversibility of
delirium; the frequent use of deliriogenic medications, and the delirium experience in the
context of end of life.
Challenges for Conducting Research in a Vulnerable Population—Most patients
referred for specialist palliative care have a cancer diagnosis and often have advanced
disease.16,17 Conducting delirium research in the advanced cancer population or in any end-
of-life condition is challenging because of patient vulnerability, ethical issues around
informed consent, and willingness of patients to participate in research, often resulting in
limited patient accrual to studies and high attrition rates.2,18 Furthermore, recruiting patients
for comparative effectiveness drug trials is challenging as many patients require
psychotropic medications for other indications, such as nausea, mood disorders, pain, and
dementia. These factors likely contribute to the reason why there is a paucity of rigorously
designed studies on the treatment of delirium in this population.
Cognitive Status and its Implications for Care—In a global aging population,
dementia presents an increasing health issue, especially in palliative care, in which there is a
predominance of elderly patients. Furthermore, dementia is regarded as an end-of-life
condition and an indication for palliative care involvement. Regardless of palliative care
involvement, mortality rates within six months of a delirium episode superimposed on
dementia are high.19 Dementia is one of the strongest risk factors for the development of
delirium in the elderly.20 When an episode of delirium is superimposed on undiagnosed
dementia, challenges may clearly arise in relation to health care decision making.
Furthermore, failure of a delirium episode to fully resolve may in itself unmask an evolving
dementia and also create challenges for health care decision making, especially when the
goals of care have not been clearly established. Patients with cognitive impairment as part of
delirium or dementia who require pain management pose unique challenges, in terms of both
assessment and the use of opioids and other pharmacologic agents.21
Determining the Reversibility of Delirium—Some studies have described the
multifactorial etiology of delirium in palliative care settings.22–24 Up to 50% of delirium
episodes in palliative care patients are reversible.22 Reversibility correlates with the type of
identified precipitating factor/s: There is a higher likelihood of reversing an episode of
delirium that is precipitated by medications, electrolyte abnormalities, and infection.23
Patients are less likely to improve if they have had previous episodes of delirium or have a
delirium related to hypoxic or global metabolic encephalopathy.22,23 The ultimate decision
to pursue investigation and treatment of delirium precipitants in palliative care settings will
depend on the goals of care and the patient’s location along the disease trajectory.25 Given
that palliative care is delivered in a variety of settings—from home to standalone inpatient
hospice units providing end-of-life care and increasingly through hospital consult teams in
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acute care settings26—varying access to investigation and treatment of delirium precipitants
also may determine the level of therapeutic intervention. Taken together, these factors may
influence the spectrum of intensity in relation to therapeutic intervention, marked by polar
extremes: one is therapeutic nihilism with potentially reversible episodes neglected and the
other is overly aggressive treatment adding burden and morbidity at the end of life. The
fundamental principles of palliative care support an individualized approach to the ultimate
decision regarding the identification and management of precipitants.
Delirium Experience in the Context of End of Life—A multidisciplinary session at
the delirium study planning meeting was devoted to examining aspects of the delirium
experience. A high level of distress has been reported by the families and the caregivers of
patients with delirium in palliative care settings.27–31 Palliative care by definition involves
multidisciplinary team delivery of care not only for the patient but also for the family.32 This
collaborative input is likely to be particularly useful in the context of delirium: Both support
and education for the family are considered essential components of a delirium management
plan.10,14,33–35 Despite the recognition of the value of family involvement and support by
published clinical guidelines (low strength of evidence), the effectiveness and impact of this
aspect of care has not been studied.
Pharmacologic Interventions
Review of Frequently Used Deliriogenic Medications—As discussed and explored
at the delirium study planning meeting, an important component of the initial management
of delirium is the identification of reversible causes, including targeted medications. A drug
profile review by a pharmacist is invaluable.36 Medications commonly implicated in
precipitating delirium in palliative care include benzodiazepines, corticosteroids,
anticholinergics, opioids, and other psychoactive medications.23,37–40 Opioids are
commonly used in palliative care, and their neuropsychiatric side effects, often collectively
referred to as opioid-induced neurotoxicity (OIN), commonly occur in patients with
advanced disease.37,41 In addition to delirium, hallucinations (usually visual or tactile) and
cognitive impairment, the other features of OIN are severe sedation, myoclonus, seizures,
allodynia, and hyperalgesia.37 Although most often described with high doses of opioids, a
twofold increased risk for delirium also has been reported at lower doses.39 Other factors
predisposing to the development of OIN include a rapid escalation in opioid dose,
dehydration, renal failure, infection, older age, borderline cognitive impairment,
concomitant use of other psychoactive medications, and a prior episode of OIN.37 OIN is
managed by opioid rotation or switching and/or dose reduction.42,43 Hydration of the patient
is also proposed as part of the OIN treatment strategy.44 The subcutaneous route is
frequently used in palliative care settings if necessary. The doses of other contributing drugs
(benzodiazepines, corticosteroids, anticholinergics, and psychotropics) should be evaluated
for necessity, duplication, drug interactions, administration schedule, and minimally
effective dose to minimize the risk for adverse events and impact on cognition and delirium.
It has been estimated that approximately 70% of drug-induced delirium episodes resolve
with opioid rotation and discontinuation of other drugs.22 Conversely, undertreated pain also
has been shown to be a risk factor for delirium in elderly hip fracture patients.45
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Antipsychotic Medications for the Symptomatic Treatment of Delirium—Our
literature search of delirium treatment yielded 15 prospective cohort studies,46–60 15
randomized controlled trials (RCTs), and one post hoc analysis of an RCT.61–76 Among the
15 prospective cohort studies (Table 1), sample sizes ranged from 10 to 79 patients and
evaluated the response to treatment with primarily atypical antipsychotics, with one study of
haloperidol and another of rivastigmine.48,60 Most trials were small in nature and describe
the resolution or improvement of symptoms associated with delirium over five to seven days
with minimal evidence of serious adverse events. Four of the 15 trials (139 patients)
evaluated hospitalized cancer patients.46,47,58,60 No study specifically sought to evaluate
these drugs in the palliative care setting.
Of the 16 RCTs (including the one post hoc analysis of an RCT), sample sizes ranged from
15 to 101 patients (Table 2). Seven trials were placebo controlled, and the remaining eight
trials were active comparator controlled. Studies involved typical and atypical
antipsychotics, dexmedetomidine, rivastigmine, lorazepam, and one study evaluated
ondansetron. Placebo-controlled trials typically allowed rescue therapy (most commonly
haloperidol) and were generally found to be associated with faster resolution of symptoms
(quetiapine)63,66,70 or reduce the likelihood of progressing from subsyndromal delirium to
active delirium (risperidone).62 There is no convincing evidence to suggest that any one
agent or drug class is superior to another; however, most trials were small in size. The
exception is rivastigmine, which was shown to be associated with increased mortality
compared with placebo,65 and thus, all cholinesterase inhibitors should be avoided in the
treatment or prevention of delirium. The delirium assessment tools used were highly
variable as were the methods used to identify adverse events. Most patients studied were
either postoperative patients or critically ill patients. Palliative care patients have not been
specifically studied in the RCTs that were identified in our literature search, except for one
study of 30 terminally ill AIDS patients, in which both haloperidol and chlorpromazine were
independently found to be more effective than lorazepam.76 At our meeting, the progress of
a large Australian multisite placebo RCT of oral risperidone vs. oral haloperidol in palliative
care patients was reported as nearing completion.77
Our literature search identified few RCTs of treatment interventions for delirium in most
settings, particularly in palliative care settings. The generalizability of study findings from
other care settings to those of palliative care is often limited, so cautious interpretation is
advised in relation to the unique contextual aspects of palliative care. Although the need for
collaborative multisite RCTs in palliative care populations is evident,78,79 it also is
important to recognize that uncontrolled open and retrospective studies in palliative care
patients may contribute pragmatic evidence that speaks to the contextual issues in this
patient population (although not reviewed here).46,47,58,80
Despite moderate to low level of evidence for drug treatment in palliative care populations,
antipsychotics are frequently used to relieve delirium symptoms, particularly perceptual
disturbance or agitation.81–85 Haloperidol remains the “practice standard” for short-term
symptom control and is regularly given to patients with clinical or hyperactive delirium
either orally, via feeding tubes, intravenously, subcutaneously, or intramuscularly.7,86,87
Oral haloperidol undergoes extensive first-pass metabolism, with an average oral
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bioavailability of 60% (range, 44%–75%).88 Thus, the parenteral potency of haloperidol is
approximately double that of enteral doses. The time to peak plasma concentration of
haloperidol is two to six hours for oral doses, whereas intravenous/intramuscular/
subcutaneous doses have a much faster onset of action, with a time to peak plasma
concentration of 10–20 minutes for the subcutaneous route.89 The half-life of haloperidol
ranges from 12 to 35 hours, with an average of 16 hours.88 Consensus guidelines
recommend initial haloperidol doses of 1–2 mg orally every two to four hours as needed and
commencing at lower doses (0.25–0.5 mg) in the elderly.9 The dose should be titrated to the
lowest effective dose to minimize adverse events and side effects. If delirium clearly
resolves, a trial of discontinuation (of drug therapy for treatment) should be considered.
Slower dose titration is often warranted in the elderly to minimize side effects.
Most studies outside the critical care settings report haloperidol dose ranges of 2–10 mg/
day,90 with higher daily haloperidol doses for hyperactive delirium compared with mixed
and hypoactive subtypes.90 Much higher doses of haloperidol have been used historically in
the intensive care settings,91,92 in which it is still commonly used.93 However, there is
currently no evidence that the duration of delirium is reduced with haloperidol treatment in
adult intensive care patients94 or in other patient populations.
In palliative care patients, hypoactive delirium is the most common subtype reported.1,95–98
A recently published study in hospital inpatients with cancer reported a higher prevalence of
perceptual disturbances and delusions in hypoactive delirium than previously reported.99
Practice varies in the management of hypoactive delirium from “as needed” dosing to
regularly scheduled haloperidol (or alternative antipsychotic) dosing regimens.6,7,100
Algorithms have been proposed for delirium pharmacotherapy in palliative care that stratify
dosing according to presenting motor subtype.101 Antipsychotics should be used with
caution in patients with Lewy-body dementia, Parkinson dementia, and Parkinson disease
because of the risk of extrapyramidal side effects (EPS).
Our literature search confirmed that there remains a relative lack of comparative trials of
atypical antipsychotics with conventionally accepted therapies such as haloperidol in the
management of delirium85 (Table 2). Atypical antipsychotics, such as risperidone,
olanzapine, quetiapine, and aripiprazole, tend to be used second-line if there are
contraindications or side effects, such as acute drug-induced extrapyramidal symptoms, with
typical antipsychotics,7,102,103 although the trials identified were not powered to show this.
Adverse Effects of Antipsychotics—From our literature search, all trials evaluated
adverse events in some form but were also underpowered to confidently compare adverse
events between treatments. EPS are the most commonly reported adverse event and are
reported for both typical and atypical agents without any strong signal of greater incidence
or prevalence for one agent over another. This is in contrast to the notion that atypical
antipsychotics have a lower propensity to cause EPS as D2 receptor blockade is mitigated
because of their antagonism at both the 5-HT2A and the muscarinic M1 receptors.103 Larger
trials will be needed to adequately address the comparative safety of these agents in
palliative care settings.
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EPS have been reported commonly in the psychiatric population taking conventional
antipsychotics. Palliative care patients are usually treated with lower antipsychotic doses for
shorter periods compared with psychiatric populations. Clinically, acute EPS are often
missed or misdiagnosed,104 and the prevalence in the palliative care population is not clear.
However, a low frequency of EPS has been reported in delirium treatment studies even
when a specific EPS instrument is used.81,101 Most instruments for the assessment of acute
EPS were developed for acutely psychotic or schizophrenic patients and are lengthy to
administer. The development and validation of standardized EPS instruments in palliative
care patients is required.
There is a large interindividual variation in propensity to develop EPS. Risk factors include
age (older patients and less than 30 years old), neuroleptic potency, and a high rapidly
increasing neuroleptic dose on treatment initiation and in slow metabolizers of CYP2D6
substrates. Older patients have a further increased risk if they also have dementia.88 For
haloperidol, a lower incidence of EPS with parenteral (intravenous or intramuscular) route
administration compared with other routes has been described.105 As a temporary solution to
alleviate EPS, an oral anticholinergic, such as benzatropine, may be administered. If
discontinuation of the antipsychotic medication is not possible, then it can be switched to
one with a lower risk of EPS.
Typical and atypical antipsychotics are associated with a prolonged QTc interval. The risk
of wide complex ventricular tachyarrhythmias and sudden death is potentiated by
combinations of medications often used in palliative care and oncology care that also
prolong the QTc interval106,107 (See www.azcert.org for a list of QT prolonging drugs and
drug interactions.). Assessment of risk factors (congenital long QT syndrome, hypokalemia,
hypomagnesemia, hypocalcemia, >65 years of age, female gender, conductive cardiac
abnormalities, and hypothyroidism) is advisable before initiating therapy.108,109 The
haloperidol (or other antipsychotic drug) dose may need to be reduced or discontinued
(along with other contributory medications) if the QTc interval is >450 ms for males and
>470 ms for females110 or increases more than 25% from baseline.9 Pharmacy and
cardiology consultations should be considered.
An U.S. Food and Drug Administration alert was issued in September 2007 recommending
electrocardiogram (ECG) monitoring if haloperidol is given by the intravenous route.111
Baseline ECG and ECG monitoring also have been recommended independent of the route
of antipsychotic administration, especially with high doses,7,102 but this resource may be a
challenge in some settings, especially in the community and at the end of life when the goals
of care are focused on patient comfort. Evidence from cohorts of palliative care and hospital
inpatients treated with haloperidol suggests that severely prolonged QTc intervals (>500 ms)
are rare, occurring in less than 1% of patients.106,112 Future studies of antipsychotic drug
treatment and prophylaxis should incorporate ECG monitoring for QTc prolongation.102
The use of both atypical and typical antipsychotics in the elderly has been associated with an
increased risk of cerebrovascular events and mortality, especially in patients with dementia
taking antipsychotics for a median of 60–110 days.113,114 In contrast, antipsychotic
treatment for delirium tends to be short term, and a recent nested case-control analysis found
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no significant increase in mortality in elderly delirious patients who received antipsychotics
compared with a group who did not.115
Other Medications in the Pharmacologic Treatment of Delirium—
Psychostimulants, such as methylphenidate, have been used in the management of patients
with hypoactive delirium,116 but the level of evidence is currently limited.102
Psychostimulants may exacerbate or cause agitation. Other possible adverse effects include
hallucinations, restlessness, insomnia, and cardiovascular effects. As benzodiazepines may
precipitate or exacerbate delirium in this patient population, they are not routinely used
unless the delirium is caused by benzodiazepine or alcohol withdrawal or is related to
seizures. In patients with uncontrolled agitation, benzodiazepines may have a limited role in
combination with an antipsychotic but not as single agents.7,9
Emerging Drugs—A role for other drugs in delirium management has been reported,
including melatonin in the postoperative setting,117 modafinil,102 valproate,118
ondansetron,61,119 and gabapentin as an adjuvant treatment.120 The use of
acetylcholinesterase inhibitors has been reported in case reports and postoperative
studies.121–124 In addition, a recent placebo-controlled randomized trial of rivastigmine add-
on therapy for delirium treatment in intensive care patients was discontinued because of
safety concerns.65 A role for statins in both the treatment and the prevention of delirium in
critically ill patients has been postulated.125,126 With proinflammatory cytokines involved in
the pathophysiology of delirium, future studies may examine the role of anti-inflammatory
medications as adjuvant agents in combination with other medications.
Continuous Sedation at the End of Life—Refractory agitated delirium at the end of
life will often necessitate the use of more sedating medications to ensure patient
symptomatic relief and comfort when other interventions have failed.127,128 The most
common medications used to effect sedation for refractory delirium at the end of life are
methotrimeprazine, chlorpromazine, midazolam, and phenobarbital.129 Methotrimeprazine
(levomepromazine), a phenothiazine, is often used in agitated delirium at the end of life, in
which its sedative properties and subcutaneous route of administration are
advantageous.87,130,131 However, it is not available worldwide including in the United
States.
Nonpharmacologic Management of Delirium
As discussed at our international delirium study planning meeting, much of the literature on
nonpharmacologic strategies is derived from management approaches with older general
medical patients and in the intensive care setting. Using a multidisciplinary team is thought
to be beneficial, but results are not consistent.132,133
Simple environmental strategies are often underutilized.102,134–136 Noise, excessive light,
excessive darkness, and frequent staff and room changes should be minimized. The family
can assist in the frequent reorientation of the delirious patient. An orientation board that is
updated daily and a visible clock should be made available in patients’ rooms.
Communication should be clear and simple, and special attention made to the importance of
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glasses for vision correction, hearing aids, and dentures. The environment needs to be
physically safe for the patient, as well as staff and family, and physical restraints avoided.
Patients’ hydration and nutrition should be monitored. Specially setup delirium rooms may
have a role but need further evaluation.137 Utilization of a brief psychoeducational leaflet on
delirium may benefit family members.33 Emotional support should be provided for family
distress, and debriefing may be necessary for patients who have recovered from an episode
of delirium.13 It is essential that pain is controlled45 and the sleep-wake cycle is normalized,
with blinds opened during the day, background noise at night minimized, and excessive
daytime napping discouraged where possible.6
Research Agenda for Delirium Management in Palliative Care
To strengthen the evidence base for current delirium practice, further good quality multisite
studies are needed.78,138,139 Most of the delirium research to date has focused on describing
the epidemiology and associated harms of delirium in a variety of affected patients, although
it has rarely focused on palliative care. There also has been a considerable amount of
literature published on the diagnosis of delirium and its subtypes and the “real-world”
implementation of standardized screening programs. Despite this impressive volume of
literature, the paucity of research investigating the prevention and treatment of delirium in
palliative care populations is of concern. To further complicate matters, as highlighted in
discussions among our meeting participants, the etiology of delirium appears to differ
enough between different populations (i.e., palliative care vs. intensive care unit vs.
hospitalized medical patients) to question the appropriateness of extrapolating research
findings from other populations to palliative care patients.
Future research programs should focus on the treatment and prevention of delirium in
palliative care settings. Prospective comparative RCTs are needed to evaluate drug and
nondrug therapies for treatment and prevention of delirium and its subtypes.140 These
studies must incorporate longitudinal assessment and need to be powered to address
meaningful clinical outcomes, such as quality of life, health economics, mortality, and
morbidity, not just rescue medication use and duration/severity/resolution of delirium.141
Although haloperidol is regarded as the practice standard therapy by consensus for delirium
treatment, it has never been validated in clinical trials and thus does not even have an U.S.
Food and Drug Administration indication for the treatment of delirium. This notion needs to
be challenged in a well-designed placebo-controlled trial.142 Because of a substantial
number of participant study withdrawals (as a result of clinical deterioration or death) in
palliative care populations, a palliative-modified intention-to-treat analysis should be
considered in the evaluation of RCTs.143 Drug therapy trials need to address dosing and
titration regimens (including variations in regimens according to motor subtype), different
routes of administration, and adverse events (including EPS), in addition to efficacy.140
Further epidemiologic research may be warranted to develop tools for the identification of
palliative care patients at “high risk” for developing delirium. Such tools should be validated
and used to determine eligibility for future studies of delirium prevention. Commonality in
the use of assessment tools may facilitate audits of delirium management and thus help to
establish some comparative benchmarking. Cluster randomized trials might be appropriate
Bush et al. Page 10
to address real-world barriers to implementation of a standardized approach to screening,
prevention, and treatment of delirium.144 Although not exhaustive, Tables 3 and 4 suggest
major themes for future research that would address critically important clinical questions
that would further guide the management of delirium and inform clinical practice in
palliative care.
Conclusion
In palliative care settings, research is challenging and literature data limited owing to patient
vulnerability close to the end of life, difficulty in patient accrual, and high attrition rates.
Overall, the evidence base for the management of delirium is limited by the lack of good
quality RCTs and practitioners’ practice often guided by expert opinion and clinical
guidelines. There is, therefore, an outstanding need for more collaborative research,
especially double-blind, randomized, placebo-controlled trials, to evaluate efficacious and
safe antipsychotic dosing schedules according to the different delirium subtypes and
etiologies in the management of delirium in palliative care patients. Comprehensive
multifaceted evidence-based interventions in the domains of prevention and environment,
combined with effective and safe pharmacologic regimens, are required, along with support
strategies for patients, families, and health care providers to reduce the impact of this
distressing complication for patients in palliative care settings. Both pragmatic and rigorous
study trial designs are essential to further our knowledge synthesis and support its
subsequent translation into clinical practice through evidence-based practice policy and
guideline development.
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Table 1
Prospective Single-Arm Studies of Pharmacologic Treatment for Delirium
Year First Author Study Design Patient Population Study Size Study Intervention Main Study Finding
2012 Kishi46 Cohort study Hospitalized cancer patients 29 Risperidone Risperidone was effective in 48% of patients,
whereas 79% showed some reduction in
delirium severity.
2011 Boettger47 Cohort Hospitalized cancer patients 21 Aripiprazole Patients exhibited significant improvement
and resolution of delirium over seven days of
treatment with aripiprazole.
2008 Oldenbeuving48 Cohort Stroke 17 Rivastigmine Delirium symptoms improved in 16 of 17
patients.
2007 Maneeton49 Cohort Hospitalized medical patients 17 Quetiapine Quetiapine was associated with an
improvement in symptoms over the seven day
study period.
2007 Takeuchi50 Cohort Hospitalized patients 38 Perospirone 87% of patients showed improvement in
delirium symptoms over a mean of five days.
The most common side effects were fatigue
(15%) and sleepiness (6%).
2006 Straker51 Cohort Hospitalized medical patients 14 Aripiprazole 12 of 14 patients had a significant reduction in
symptoms over the course of the study.
2004 Mittal52 Cohort Hospitalized medical and
surgical patients
10 Risperidone Symptomatic improvement observed over the
seven day study period.
2004 Parellada53 Cohort Hospitalized medical patients 64 Risperidone 91% of patients had symptomatic
improvement over the course of seven days.
2004 Pae54 Cohort Hospitalized medical patients 22 Quetiapine Symptomatic improvement observed in 86%
of patients over the course of seven days.
2003 Sasaki55 Cohort Hospitalized medical patients 12 Quetiapine All patients had resolution of symptoms at a
mean of five days.
2003 Horikawa56 Cohort Hospitalized medical patients 10 Risperidone Eight of 10 patients had symptomatic
improvement of delirium.
2003 Kim57 Cohort Hospitalized medical patients 12 Quetiapine Symptomatic improvement was observed over
a mean of six days.
2002 Breitbart58 Cohort Hospitalized cancer patients 79 Olanzapine 76% of patients had complete resolution of
delirium. Age>70 years was found to be the
strongest predictor of suboptimal response to
olanzapine.
2001 Kim59 Cohort Hospitalized medical and
surgical patients
20 Olanzapine Symptomatic improvement was observed over
an average course of seven days.
1996 Akechi60 Cohort Hospitalized cancer patients 10 Haloperidol Symptomatic improvement was described for
all patients over a median of six days.
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Table 3
Suggested Prospective Interventional Research Themes for Delirium Prevention and
Screening
Population Among palliative care patients at risk of, delirium …
Intervention … does delirium prevention with
pharmacotherapy …
… does delirium prevention with
nonpharmacologic measures …
… does routine and
standardized
screening for
delirium …
Comparator … compared with placebo … … compared with usual care …
Outcome … improve survival, health economics, palliative morbidity, and quality of life?
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Table 4
Suggested Prospective Interventional Research Themes for Delirium Treatment
Population Among palliative care patients with delirium or a specific delirium subtype …
Intervention … does treatment with psychoactive pharmacotherapy … … what is the incremental benefit of treatment with
psychoactive pharmacotherapy …
Comparator … compared with placebo … … compared with other active
treatments …
… compared with nonpharmacologic measures that
address precipitating factors …
Outcome … improve survival, health economics, palliative morbidity, and quality of life?
